Paradigm Pulse cover art

Paradigm Pulse

Paradigm Pulse

By: Paradigm Medical Communications LLC
Listen for free

Season's Savings | £0.99/mo for 3 months

£5.99/mo after 3 months - terms apply. Cancel monthly
Listen to audio from accredited CME activities from Paradigm Medical Communications, featuring expert faculty discussions and the latest clinical insights. Visit the link in each episode description to access the full activity and claim CME credit.© 2026 Paradigm Medical Communications, LLC Science
Episodes
  • Incorporating Updates in Advanced Thyroid Cancers: The Role of Targeted Therapies for DTC, ATC, and MTC

    Incorporating Updates in Advanced Thyroid Cancers: The Role of Targeted Therapies for DTC, ATC, and MTC
    Sep 17 2026

    This companion podcast has been adapted from the full CME activity. Please CLICK HERE or paste the following URL into your browser, (https://activities.paradigmmc.com/1444) to participate in the full CME activity (which includes the assessments, slides, interactive questions, and the evaluation) and claim credit for your participation.

    • (00:00) - Intro
    • (01:05) - Introduction to Advanced Thyroid Cancers
    • (10:36) - Understanding Advanced DTC
    • (21:13) - Overview of ATC
    • (33:03) - Understanding MTC
    • (44:15) - Conclusions

    Advanced thyroid cancers pose unique diagnostic and treatment challenges, particularly because many clinicians encounter few cases in practice. This 60-minute CME lecture will provide a concise update on the management of differentiated, anaplastic, and medullary thyroid cancers (DTC, ATC, MTC), with a focus on emerging evidence, guideline-directed care, and personalized treatment strategies. Our faculty will review the role of molecular testing and biomarkers in treatment selection, discuss current systemic therapies, and address practical approaches to monitoring and managing treatment-related adverse events (AEs) to optimize patient outcomes.

    TRANSCRIPT
    Show More Show Less
    47 mins
  • New and Emerging Mechanisms in the Treatment of Systemic Lupus Erythematosus

    New and Emerging Mechanisms in the Treatment of Systemic Lupus Erythematosus
    Aug 3 2026

    Please CLICK HERE, or paste the following URL into your browser, (https://activities.paradigmmc.com/1460P) to view the full CME activity and claim credit for your participation.

    • (00:00) - Welcome and Introduction
    • (05:54) - B Cell Targets in Lupus
    • (07:58) - Targeting BAFF
    • (11:55) - Dual Targeting APRIL and BAFF
    • (15:11) - B-Cell Depletion Via the BAFF Receptor
    • (17:57) - Type II Anti-CD20
    • (28:20) - Bispecific T-Cell Engagers
    • (32:51) - CAR-T Cells in SLE

    B cells play a major role in the pathology of systemic lupus erythematosus (SLE), and several treatments have focused on blocking activation or depleting large subsets of B cells based on surface markers. From anti-CD20 antibodies to chimeric antigen receptor (CAR) T cells, varying depths of B-cell depletion have demonstrated a range of efficacies and durations of response. In addition, these treatments vary in administration, preparation, ease of use, and potential adverse effects. The faculty will provide an engaging discussion on the categories of emerging B-cell therapies and their potential use in SLE.
    Show More Show Less
    39 mins
adbl_web_anon_alc_button_suppression_t1
No reviews yet